Biolife solutions stock.

BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.BioLife Solutions (BLFS) In a report released today, Robert Wasserman from Benchmark Co. maintained a Hold rating on BioLife Solutions. The company’s shares closed last Thursday at $11.96.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.

Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in …Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings.

Open 18.44. Day High 18.95. Day Low 18.17. Prev Close 18.25. 52 Week High 26.96. 52 Week High Date 09/08/22. 52 Week Low 10.40. 52 Week Low Date 05/12/22. Market Cap 812.385M.BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of biological materials. BioLife Solutions is one of Washington’s best places to work ...

BioLife Solutions, Inc., Bothell, Washington. 194 likes · 5 talking about this · 7 were here. Class-defining solutions for bioproduction workflows.Get the latest BioLife Solutions, Inc. (BLFS) stock news and headlines to help you in your trading and investing decisions.Get the latest BioLife Solutions, Inc. (BLFS) stock news and headlines to help you in your trading and investing decisions.BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months …

While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...

BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.

CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of biological materials. BioLife Solutions is one of Washington’s best places to work ...Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...BioLife Solutions Biopreservation Media Products Outperform Traditional, Non-Optimized Formulations BOTHELL, WA-January 27, 2012- BioLife Solutions Inc.( OTC BB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells and tissues, today …May 10, 2023 · BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.Todd Berard, BioLife's Chief Marketing Officer, commented, "With a capacity that's 40% larger than other tabletop CRFs, IntelliRate i67C is perfectly sized to efficiently scale precision rate freezing as a customer's capacity needs grow. We designed the IntelliRate i67C to increase single-batch, LN2 CRF capacity from mid- and late-stage …16 mar 2023 ... Share this article · Cell Processing platform revenue was $68.5 million, up $23.5 million, or 52%, over 2021. · Freezers and Thaw Systems platform ...BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.Description. BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted ...

Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued.

Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ...Mar 22, 2021 · Athens, Ohio, March 22, 2021 — Stirling Ultracold, a privately-held innovative developer and manufacturer of ultra-low temperature (ULT) freezers, today announced it has signed a definitive agreement to merge into BioLife Solutions (NASDAQ: BLFS) to combine expertise and expand individual product offerings for biopharma research and life ... We are revolutionizing regenerative medicine, biobanking and drug discovery by increasing the viability of biologics. BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation ...CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.Nov 28, 2023 · BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ...

intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Wednesday 11/08/2023 the closing price of the Biolife …

Dec 4, 2023 · Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,251 shares of the medical equipment provider’s stock after selling 7,097 shares during the period. Rhumbline Advisers’ holdings in BioLife Solutions were worth $1,774,000 as of its most recent […] According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $144 million to $158 million ...Dec 1, 2023 · View BioLife Solutions, Inc BLFS investment & stock information. Get the latest BioLife Solutions, Inc BLFS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued.On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis. BioLife Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated DivestitureMay 3, 2021 · BioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling. BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million , with total 2021 revenue of $101 million to $110 million . Nov 8, 2023 · Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings. BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.BOTHELL, Wash., Aug. 8, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of class-defining bioproduction tools and services for the cell ...BOTHELL, Wash., April 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an …Instagram:https://instagram. 1943d steel penny valuevwo dividendbill com newsaltria ex dividend date 2023 According to the issued ratings of 5 analysts in the last year, the consensus rating for BioLife Solutions stock is Buy based on the current 5 buy ratings for BLFS. The average twelve-month price prediction for BioLife Solutions is $24.60 with a high price target of $28.00 and a low price target of $22.00. Learn more on BLFS's analyst rating ... nvo stock forecastamerican pilot pay BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own. The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU …Name. Chg %. Market Cap. Evogene Ltd. -1.07%. $30.17M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial... what dental insurance covers dentures BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.This report will help you with various insights regarding the recent year performance of BioLife Solutions Inc (BLFS) stock.Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis.